A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

NCT01714037 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Debio 0932
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Gemcitabine
DRUG: Docetaxel

Sponsor

Debiopharm International SA

Collaborators

[object Object]